| |
Focused on accelerating gene and cell therapy from clinical to commercial, OcyonBio built two processing facilities in Puerto Rico. See how the company is now benefiting from the island's highly skilled talent, tax benefits & much more.
|
|
Today’s Big NewsMar 5, 2024 |
| By Max Bayer Biogen's executive vice president and head of corporate development, Adam Keeney, Ph.D., says the company is interested in tacking on additional rare disease drugs at a smaller price than the Reata acquisition. The focus is now on clinical-stage products compared to buying commercial medicines. |
|
|
|
By Kevin Dunleavy With the fortunes of GSK on the rise after much tumult early in the decade, the company has rewarded CEO Emma Walmsley with a significant pay boost. Walmsley collected 12.7 million pounds ($16 million) in total pay last year, a 51% increase from her compensation in 2022. |
By Conor Hale The company said it sees Attune Medical and its ensoETM as a shortcut to improving the safety of treatments for atrial fibrillation, without surgeons having to buy nascent pulsed field ablation systems. |
By Angus Liu Bill Anderson, nine months into Bayer’s CEO role, has laid out his priorities for the troubled German conglomerate in the next few years—and it doesn’t involve an immediate business split-up as many investors had hoped for. |
|
Wednesday, March 13, 2024 | 11am ET / 8am PT Extractables and leachables are a hot topic in the pharmaceutical industry today. As single-use systems, devices, and routes of administration evolve, it is important to have a strategy that helps ensure you choose proper equipment and materials, file on time, avoid repeat studies, and more. Save your spot to be a part of this insightful discussion!
|
|
By James Waldron In further proof that Roche’s $310 million metabolic therapy bet will pay off, the Big Pharma’s Alnylam-partnered hypertension drug has notched up another phase 2 win. |
By Conor Hale According to researchers, the algorithms were able to deliver 70% to 80% accuracy in forecasting efficacy outcomes and the likelihood of unwanted side effects. |
By Fraiser Kansteiner Vanda has been waiting years for an FDA hearing to contest the agency’s 2019 rejection of its sleep drug Hetlioz in jet lag disorder. Now, following a lawsuit and a protracted back-and-forth with the U.S. regulator, the FDA has crushed Vanda’s bid. |
By Gabrielle Masson Venture capital investment in biopharma underwent a significant correction in 2023 from the "explosive growth" during the pandemic, with $29.9 billion spent across 920 transactions compared to $36.7 billion in the previous year, according to a new analysis from PitchBook. |
By Kevin Dunleavy A trial by Novo Nordisk of its GLP-1 blockbuster Ozempic (semaglutide) on diabetes and kidney disease patients found that it reduced the risk of kidney disease progression, major adverse cardiovascular events (MACE) and death by 24%. |
By Conor Hale After receiving four FDA clearances for AI that spots tooth decay and gum disease, Overjet has raised $53.2 million to build a platform for dentists and payers. |
By Andrea Park Incyte has launched a new campaign to raise awareness around the often hard-to-see symptoms of myeloproliferative neoplasms, or MPNs, accompanied by AI-created images that make invisible symptoms visible and create a visual representation of some patients’ experiences with the diseases. |
By Gabrielle Masson Meissa Vaccines is putting its portfolio on hold and laying off staff due to the current fundraising environment, the company told Fierce Biotech. |
By Zoey Becker The cash and stock deal gives Telix access to ARTMS' manufacturing site, a stockpile of ultra-pure rare metals and an advanced isotope production platform. |
Fierce podcastsDon’t miss an episode |
| | The FDA recently asked the six marketed CAR-T therapies to add a new boxed warning item on their labels to reflect the risk of secondary T-cell cancers. This week on "The Top Line," Fierce Pharma’s Angus Liu talks with regulatory experts to understand the rationale behind the FDA’s decision and to discuss its implications for CAR-T candidates and their developers down the line. |
|
|---|
|
|
|
Thursday, March 28, 2024 | 11am ET / 8am PT Building a solid foundation and getting support in your journey, from critical raw materials to commercial supply, through flexible and transparent partnerships can be key in your scalable success. Don't miss this opportunity to learn how to optimize your gene therapy development. Register now.
|
|
| Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
